Print

TALAPRO-3: A Clinical Trial in Men with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) and DNA Damage Repair (DDR) Gene Alteration

https://www.facingourrisk.org/research-clinical-trials/study/153/talapro-3-a-clinical-trial-in-men-with-metastatic-castration-sensitive-prostate-cancer-mcspc-and-dna-damage-repair-ddr-gene-alteration

Clinicaltrials.gov identifier:
NCT04821622 (https://clinicaltrials.gov/show/NCT04821622)


Metastatic castration-sensitive prostate cancer

Study Contact Information:

For more information about the study, visit www.Talapro3ClinicalTrial.com


About the Study

TALAPRO-3 is a trial for men who have been diagnosed with metastatic castration-sensitive prostate cancer (mCSPC) which means that the tumor has spread to other parts of the body but is still sensitive to hormone therapies.                                                                                                                         

This clinical trial is investigating if a study drug called talazoparib, is effective and safe when given alongside enzalutamide, an existing, approved treatment for metastatic prostate cancer.

NOTE: This study is no longer enrolling patients. 


Type of Trial

People with metastatic castration-sensitive prostate cancer may be able to take part. This is a Phase 3, randomized, double blind, placebo-controlled study. The goal is to assess if talazoparib (the study drug) plus enzalutamide is more effective than enzalutamide alone in helping to delay the spread of cancer and is safe.


Taking part in the Talapro-3 study will include:

 

Study Sites

This is a global clinical research study. There are 285 study sites planned in 29 countries worldwide, including:

For more information about the study, visit www.Talapro3ClinicalTrial.com


This Study is Open To:

NOTE: This study is no longer enrolling patients. 

This Study is Not Open To:

NOTE: This study is no longer enrolling patients. 


About FORCE

FORCE is a national nonprofit organization, established in 1999. Our mission is to improve the lives of individuals and families affected by adult hereditary cancers.